XML 168 R114.htm IDEA: XBRL DOCUMENT v3.10.0.1
Other Consolidated Financial Statement Detail (Details Textual)
$ in Millions, ₩ in Billions
3 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2018
KRW (₩)
Feb. 29, 2012
USD ($)
Feb. 29, 2012
KRW (₩)
Business Acquisition [Line Items]                  
Other Liabilities, Noncurrent $ 1,389.4 $ 1,628.7   $ 1,389.4 $ 1,628.7        
Other Assets, Current 687.6 962.0   687.6 962.0        
Increase to goodwill       1,080.1 1,267.3        
Accrued construction in progress 125.2 159.7   125.2 159.7        
TECFIDERA litigation settlement charge     $ 454.8 0.0 0.0 $ 454.8      
Prepaid taxes 271.2 657.6   271.2 657.6        
Investments and other assets 1,690.6 431.6   1,690.6 431.6        
Accrued Income Taxes, Noncurrent 791.4 979.8   791.4 979.8        
Solothurn                  
Business Acquisition [Line Items]                  
Accrued construction in progress 100.0 150.0   100.0 150.0        
TECFIDERA | Fumapharm AG                  
Business Acquisition [Line Items]                  
Increase to goodwill       1,200.0 1,500.0        
TECFIDERA | Fumapharm AG | Twenty billion                  
Business Acquisition [Line Items]                  
Increase to goodwill 300.0                
TECFIDERA | Fumapharm AG | Each additional one billion up to twenty billion                  
Business Acquisition [Line Items]                  
Cumulative sales level 20,000.0     20,000.0          
TECFIDERA | Fumapharm AG | Fifteen billion                  
Business Acquisition [Line Items]                  
Cumulative sales level   15,000.0     15,000.0        
TECFIDERA | Fumapharm AG | Sixteen billion                  
Business Acquisition [Line Items]                  
Increase to goodwill   600.0              
Cumulative sales level   $ 16,000.0     $ 16,000.0        
Ionis Pharmaceuticals                  
Business Acquisition [Line Items]                  
Investment in Ionis 563.8     563.8          
Samsung Bioepis                  
Business Acquisition [Line Items]                  
Investment in Samsung Bioepis $ 680.6     $ 680.6     ₩ 759.5 $ 45.0 ₩ 49.5